MedTrace Logo

Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)

NCT00390585 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2010-03-15

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that Iodixanol 320 is associated with a lower incidence of contrast-induced nephropathy (CIN) when compared with hyperosmolar contrast medium Iomeprol 350 in patients with impaired renal function undergoing percutaneous coronary interventions (PCI).

Conditions

  • Renal Insufficiency, Chronic
  • Angioplasty, Transluminal, Percutaneous Coronary
  • Coronary Arteriosclerosis

Interventions

DRUG

Iodixanol 320

Iodixanol 320 is used as contrast media while coronary intervention.

DRUG

Iomeprol 350

Iomeprol 350 is used as contrast media while coronary intervention.

Sponsors & Collaborators

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Albert Schoemig, MD · Deutsches Herzzentrum Muenchen

  • Rainer Wessely, MD · Deutsches Herzzentrum Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-01-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00390585 on ClinicalTrials.gov